Compounds > caldaret
Page last updated: 2024-12-11

caldaret

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

caldaret: may have cardiotonic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6433076
CHEMBL ID2106572
SCHEMBL ID1650574
MeSH IDM0467949

Synonyms (24)

Synonym
caldaret
5-methyl-2-piperazin-1-ylbenzenesulfonic acid
benzenesulfonic acid, 5-methyl-2-(1-piperazinyl)-
5-methyl-2-(piperazin-1-yl)benzenesulfonic acid
133804-44-1
unii-9l3y3ij2hi
9l3y3ij2hi ,
mcc 135
caldaret [inn]
CHEMBL2106572
5-methyl-2-(1-piperazinyl)benzenesulfonic acid monohydrate
SCHEMBL1650574
5-methyl-2-(1-piperazinyl)benzenesulfonic acid
5-methyl-2-(1-piperazinyl)-benzenesulfonic acid
DCDFLGVJWQIRGH-UHFFFAOYSA-N
2-(1-piperazinyl)-5-methylbenzenesulfonic acid
DTXSID80158376
CS-0018450
HY-100298
5-methyl-2-(1-piperazinyl) benzenesulfonic acid
DB06231
EX-A7625
Q27272692
AKOS040741497

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" MCC-135 appeared to be safe and well tolerated."( A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular sal
Hibberd, MG; Jang, IK; Pettigrew, V; Picard, MH; Shen, S; Tatsuno, J; Tzivoni, D; Wackers, FJ; Weissman, NJ; Zile, MR, 2008)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.36 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (46.15%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (53.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
diltiazem
Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.		2.03105-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
monensin
Monensin: An antiprotozoal agent produced by Streptomyces cinnamonensis. It exerts its effect during the development of first-generation trophozoites into first-generation schizonts within the intestinal epithelial cells. It does not interfere with hosts' development of acquired immunity to the majority of coccidial species. Monensin is a sodium and proton selective ionophore and is widely used as such in biochemical studies.. monensin A : A spiroketal, monensin A is the major component of monensin, a mixture of antibiotic substances produced by Streptomyces cinnamonensis. An antiprotozoal, it is used as the sodium salt as a feed additive for the prevention of coccidiosis in poultry and as a growth promoter in cattle.		2.0210cyclic hemiketal;
monocarboxylic acid;
polyether antibiotic;
spiroketal		antifungal agent;
coccidiostat;
ionophore
beta-escin
[no description available]		2.0110
cardiovascular agents
Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.		3.4311
ConditionIndicatedRelationship StrengthStudiesTrials
Left Ventricular Dysfunction
[description not available]		08.4311
Cardiovascular Stroke
[description not available]		06.0665
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		06.0665
Ventricular Dysfunction, Left
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.		03.4311
Cardiac Failure
[description not available]		03.411
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		03.411
Injury, Myocardial Reperfusion
[description not available]		04.3241
Alloxan Diabetes
[description not available]		02.0110
Diabetic Angiopathies
VASCULAR DISEASES that are associated with DIABETES MELLITUS.		02.4120
Cardiomyopathies, Primary
[description not available]		02.4120
Cardiomyopathies
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).		02.4120
Injury, Ischemia-Reperfusion
[description not available]		02.0210
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		02.0210
Acute Disease
Disease having a short and relatively severe course.		03.4111
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		03.4111